DURHAM, N.C., May 14, 2024 /PRNewswire/ -- Community research provider EmVenio Research and technology company, Health Wizz are pleased to announce a new partnership to address site management and participant engagement in clinical trials. This collaboration unites the strengths of both companies in the areas of Localization and Hybrid Clinical Trials, offering a comprehensive, turn-key solution to healthcare providers and systems eager to participate in clinical research and trials.
Key Points:
- DURHAM, N.C., May 14, 2024 /PRNewswire/ -- Community research provider EmVenio Research and technology company, Health Wizz are pleased to announce a new partnership to address site management and participant engagement in clinical trials.
- Reflecting on this partnership, Raj Sharma, CEO of Health Wizz, stated, "We are thrilled to join forces with EmVenio Research, a leader in site and trial management.
- Echoing these sentiments, Mark McKenzie, MD of EmVenio Research, remarked, "Our collaboration with Health Wizz represents a significant milestone in our mission to innovate clinical research.
- By integrating advanced technology with expert trial management, Health Wizz and EmVenio Research are simplifying the path for healthcare providers to engage in clinical research and trials.
Technology,
Men,
LGBTQ+,
Professional Services,
DEI (Diversity, Equity and Inclusion),
Consumer,
Clinical Trials,
Diabetes,
Health,
Apps,
Applications,
Generation Z,
Generation X,
Other Consumer,
Mobile,
Wireless,
Baby Boomers,
Women,
Pharmaceutical,
Boehringer Ingelheim,
Heart,
Overweight,
Death,
Partnership,
Research,
Medicine,
Environment,
Obesity,
Senior,
Patient,
Multimedia,
Boehringer,
Clinical trial,
Pharmacy,
Pharmaceutical industry Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
Key Points:
- Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable.
- View the full release here: https://www.businesswire.com/news/home/20240502134064/en/
Through this collaboration, Boehringer Ingelheim will leverage select Walgreens community pharmacies as clinical trial sites for people living with obesity, overweight and type 2 diabetes.
- “Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation,” said Ramita Tandon, Chief Clinical Trials Officer at Walgreens.
- “Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio,” said Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim U.S. “By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials.
Hospital,
Prime Healthcare Services,
Health care,
EHR,
MD,
Partnership,
Research,
Electronic health record,
ChromeOS,
Patient,
Failure,
Community,
Prime,
Wolfram,
Nursing DURHAM, N.C., April 16, 2024 /PRNewswire/ -- Community research provider EmVenio Research and Prime Healthcare, an award-winning national health system, today announce their partnership to launch the EmVenio Research Center at Prime Healthcare. The partnership allows EmVenio to conduct research at Prime Healthcare hospitals and offer Prime's patients improved access to clinical research. The approach aims to increase participation in clinical trials by creating community awareness of research and offering those communities local access to global research opportunities, while also expanding the options Prime Healthcare offers its patients.
Key Points:
- DURHAM, N.C., April 16, 2024 /PRNewswire/ -- Community research provider EmVenio Research and Prime Healthcare, an award-winning national health system, today announce their partnership to launch the EmVenio Research Center at Prime Healthcare.
- The partnership allows EmVenio to conduct research at Prime Healthcare hospitals and offer Prime's patients improved access to clinical research.
- Through the partnership, EmVenio will work with Prime Healthcare hospitals to help identify potential candidates for clinical trials via Health Wizz.
- This distinctive collaboration among EmVenio Research, Prime Healthcare, and Health Wizz marks a significant milestone in EmVenio's evolution and service repertoire.
Retrieved on:
Friday, February 23, 2024
African Americans,
Acquisition,
CTS,
FDA,
Hispanic,
RFP,
Patient,
Clinical trial,
DCTS,
Research,
Travel DENVER, Feb. 23, 2024 /PRNewswire/ -- Denver-based PCM Trials, the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina. EmVenio is the largest provider of community-based clinical trial sites served with mobile research units. The acquisition, which is effective immediately, strengthens PCM Trials' and EmVenio's abilities to recruit and retain diverse populations for clinical research studies, as required for regulatory approval. Site networks are key to delivering critical study data for sponsors; by combining capabilities with EmVenio, PCM Trials now has access to a site network that is focused on serving underrepresented patient populations in previously hard-to-reach communities and can work flexibly with sponsors to achieve their study goals.
Key Points:
- DENVER, Feb. 23, 2024 /PRNewswire/ -- Denver-based PCM Trials , the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina.
- The acquisition, which is effective immediately, strengthens PCM Trials' and EmVenio's abilities to recruit and retain diverse populations for clinical research studies, as required for regulatory approval.
- "The acquisition of EmVenio is an important part of our company's overall strategy to further remove barriers for patients of all backgrounds and ethnicities to participate in clinical research, creating the most patient-centric clinical trial model," said Greg Austin, President of PCM Trials.
- On January 10, the company announced the acquisition of Netherlands-based Clinical Trial Service (CTS), which solidified PCM Trials' ability and reach to successfully conduct global clinical trials.
Retrieved on:
Thursday, September 21, 2023
Molecular biology,
Doctor of Medicine,
University,
Diabetes,
Internal medicine,
Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States,
Physician,
American Board of Internal Medicine,
Georgetown University School of Medicine,
Cardiovascular disease,
Infection,
University School,
Physiology,
DRS,
Research,
Georgetown University,
American Board of Commissioners for Foreign Missions,
Health care access among Dalits in India,
Indiana University School of Medicine,
Surgeon,
Accreditation,
Knowledge,
Growth,
Jan Vansina,
National Board of Medical Examiners,
Pharmaceutical industry,
Medical device,
Nursing,
Science,
Indiana University DURHAM, N.C., Sept. 21, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Michelle Mallitz, M.D. and Thomas Wade, M.D. to its team to serve as principal investigators. In their roles, they will oversee and conduct objective clinical research to ensure independent, high quality and reproducible results, as well as manage oversight of compliance, financial, personnel and other related aspects of research projects. Coming from varying medical backgrounds, Drs. Mallitz and Wade bring a depth of knowledge and experience to the EmVenio team, allowing the research organization to conduct trials addressing a wider range of infectious diseases and therapeutic areas.
Key Points:
- DURHAM, N.C., Sept. 21, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Michelle Mallitz, M.D.
- "The addition of these two incredible principal investigators is proof that EmVenio's growth is focused on quality and not quantity," said Thad Wolfram, EmVenio president.
- "These individuals bring a level of expertise and skill that opens more doors for our team to conduct a multitude of research studies for pharmaceutical sponsors and clinical research organizations.
- Dr. Thomas Wade holds nearly 23 years of medical practice and clinical research experience, serving as a principal investigator and practicing internal medicine.
Retrieved on:
Thursday, September 14, 2023
DURHAM, N.C., Sept. 14, 2023 /PRNewswire/ -- EmVenio Research , a global network of mobile research sites providing localized trial access to diverse and underserved communities, today announced a strategic partnership with RealTime Software Solutions, LLC , a renowned provider of cutting-edge, digitally-optimized technologies designed for clinical research sites, CROs (clinical research organizations) and sponsors.
Key Points:
- DURHAM, N.C., Sept. 14, 2023 /PRNewswire/ -- EmVenio Research , a global network of mobile research sites providing localized trial access to diverse and underserved communities, today announced a strategic partnership with RealTime Software Solutions, LLC , a renowned provider of cutting-edge, digitally-optimized technologies designed for clinical research sites, CROs (clinical research organizations) and sponsors.
- "RealTime Software Solutions offers a comprehensive tool that will enable the EmVenio team to standardize and optimize research processes to ultimately deliver high-quality data to our sponsors and CROs," said Mark Campbell, EmVenio's chief operating officer.
- RealTime Software Solutions provides a robust full-stack Site Operations Management System (SOMS) for clinical research, empowering EmVenio to streamline research processes, enhance efficiency and foster innovation.
- This partnership will allow EmVenio to remain focused on its core mission of delivering localized trial access while harnessing RealTime Software Solutions' technology to efficiently manage research operations.
Institutional review board,
Podiatry,
Federal Drug Control Service of Russia,
Gastroenterology,
Diabetes,
Scheuring,
Public,
Leather,
Clinical trial,
Assessment,
Consultant,
Employment,
Research,
Bachelor of Arts in Clinical Psychology,
Organization,
Creighton University,
Dermatology,
International Conference on Mechanical Industrial & Energy Engineering,
Food and Drug Administration,
Adaptive participatory integrated approach,
Quality control,
Harmonization,
Conference,
Nursing,
Western Kentucky University DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes. Scheuring serves as director of quality and compliance and Leathers is the manager of clinical research education and training. Their hiring aligns with EmVenio's goal to ensure that the clinical trial team conducts and will maintain adherence to the latest Federal Drug Administration regulations and in accordance with Good Clinical Practice and International Conference of Harmonization guidelines.
Key Points:
- DURHAM, N.C., Aug. 28, 2023 /PRNewswire/ -- EmVenio Research recently appointed Christine Scheuring and Vickie Leathers to manage clinical research teams and processes.
- Scheuring serves as director of quality and compliance and Leathers is the manager of clinical research education and training.
- EmVenio Research appointed Christine Scheuring and Vickie Leathers to manage its clinical research teams and processes.
- "Adding Christine and Vickie reinforces our research team's effort to remain on the forefront of developments in the clinical research realm."
Vaccine,
Emory University,
Endometriosis,
Bachelor of Science in Human Biology,
College,
Diabetes,
Internal medicine,
Youngstown, Ohio,
The College of Medicine,
Nephrology,
American Board of Internal Medicine,
MT,
Chapel Hill,
Medical school,
Medical Association of Georgia,
Youngstown State University,
Research,
Oregon Health & Science University,
Medicine,
Infection,
Certification,
Bachelor of Arts in Clinical Psychology,
Chemistry,
American Board of Commissioners for Foreign Missions,
Alaska Federal Health Care Access Network,
Kidney,
Patient,
University,
Anemia,
University of North Carolina School of Law,
Northeast Ohio Medical University,
Uterine fibroid,
California Community College Athletic Association,
Obstetrics,
Knowledge,
Pharmacology,
Medical device,
Nursing,
Science,
DRS DURHAM, N.C., Aug. 1, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Dr. Stephen Blank, M.D., and Dr. Suzanne Swan, M.D., to its team, serving as principal investigators. In their roles, they will oversee and conduct objective clinical research to ensure independent, high quality and reproducible results, as well as manage oversight of compliance, financial, personnel and other related aspects of research projects. Coming from varying medical backgrounds, Dr. Blank and Dr. Swan offer a diversity of expertise, expanding EmVenio's ability to conduct a wider range of clinical trials.
Key Points:
- DURHAM, N.C., Aug. 1, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Dr. Stephen Blank, M.D., and Dr. Suzanne Swan, M.D., to its team, serving as principal investigators.
- Stephen Blank and Suzanne Swan to its team of principal investigators.
- Blank and Swan bring to our team a magnitude of experience and knowledge in the research of new treatments and therapies," said Thad Wolfram, EmVenio president.
- "With their diverse backgrounds in medicine, they offer a unique level of oversight to the studies EmVenio conducts and provide our organization the depth to conduct a wider range of clinical research studies for pharmaceutical and clinical research organizations."
Partnership,
Education,
Clinical trial,
Infection,
Research,
NLP,
Community,
Algorithm,
Patient,
AI,
Benchmarking,
ChromeOS,
Pharmaceutical industry DURHAM, N.C., July 27, 2023 /PRNewswire/ -- Community research provider EmVenio Research today announced a partnership with TrialHub , a data intelligence platform that delivers real-time patient insights and empowers EmVenio to conduct a wider range of clinical trials for new life-saving treatments.
Key Points:
- DURHAM, N.C., July 27, 2023 /PRNewswire/ -- Community research provider EmVenio Research today announced a partnership with TrialHub , a data intelligence platform that delivers real-time patient insights and empowers EmVenio to conduct a wider range of clinical trials for new life-saving treatments.
- Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed to support pharmaceutical sponsors and clinical research organizations' participation goals.
- By working with TrialHub, EmVenio will donate a full patient scholarship to the European Patients' Academy on Therapeutic Innovation 's Patient Expert program.
- "An organization of true patient champions, recently EmVenio achieved over 44% diversity in infectious disease studies by providing convenient access to clinical research sites.
DURHAM, N.C., June 20, 2023 /PRNewswire/ -- Community research provider EmVenio Research today announced its international expansion with the launch of research operations in the United Kingdom. In collaboration with EMS Healthcare, the U.K.'s largest mobile clinical research partner, they will – together – operate a range of commercial clinical trials in 10 mobile sites identified by EMS, across England, Wales and Scotland. The expansion into the U.K. allows EmVenio to garner a wider demographic of research participants and diversify its clinical trial offerings, based on the needs of pharmaceutical sponsors and contract research organizations, as well as having a positive impact on health outcomes in Britain.
Key Points:
- U.S.-based researcher and EMS Healthcare collaborate to conduct commercial clinical trials through a network of mobile research sites.
- DURHAM, N.C., June 20, 2023 /PRNewswire/ -- Community research provider EmVenio Research today announced its international expansion with the launch of research operations in the United Kingdom.
- In collaboration with EMS Healthcare , the U.K.'s largest mobile clinical research partner, they will – together – operate a range of commercial clinical trials in 10 mobile sites identified by EMS, across England, Wales and Scotland.
- EmVenio currently operates research in 10 mobile community research sites across the United States, supporting a variety of indications that help to address community-specific health trends and current needs.
